Braftovi + Mektovi Available Now
Onco360 selected to participate in the limited distribution network for Array Biopharma’s new products BRAFTOVI™(encorafenib) and MEKTOVI® (binimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test.
“BRAFTOVI and MEKTOVI provide another important therapeutic option for patients with unresectable or metastatic melanoma with BRAF B600E or BRAFV600K mutations,” said Onco360 President and CEO Paul Jardina. “The world’s top biopharmaceutical companies, including Array Biopharma, continue to leverage Onco360’s patient-centric approach to cancer care when choosing a pharmacy network to distribute their pioneering new treatments in oncology. We are pleased to have been selected to join the limited distribution network for BRAFTOVI and MEKTOVI and look forward to providing outstanding care to patients who have a critical need for this therapy.”
BRAFTOVI and MEKTOVI were approved by The U.S. Food and Drug Administration (FDA) on June 27, 2018 based on clinical data from the Phase 3 COLUMBUS study, published in the Lancet Oncology.1 Braftovi Prescribing Information. Mektovi Prescribing Information.
Metastatic melanoma is the most life-threatening type of skin cancer, associated with low survival rates. An estimated half of the 200,000 new cases of melanoma diagnosed worldwide each year have BRAF mutations, a key target in the treatment of metastatic melanoma.
1Ascierto PA, et al. Lancet Oncol. 2016;17:1248-1260